Participants with therapies by final study diagnosis
| Therapy class . | Final study diagnosis . | |||||||
|---|---|---|---|---|---|---|---|---|
| MDS (n = 256) . | MDS/MPN overlap (n = 45) . | ICUS (n = 48) . | AML with <30% blasts∗ (n = 14) . | Other AML (n = 3) . | Other malignancy (n = 11) . | Other (n = 41) . | Total (n = 418) . | |
| Any therapy† | 111 (43%) | 22 (49%) | 2 (4%) | 12 (86%) | 1 (33%) | 2 (18%) | 4 (10%) | 154 (37%) |
| Antineoplastic agent‡,§ | 93 (84%) | 17 (77%) | 1 (50%) | 11 (92%) | 1 (100%) | 2 (100%) | 3 (75%) | 128 (83%) |
| Hypomethylating agent§ | 80 (72%) | 12 (55%) | 1 (50%) | 8 (67%) | 0 (0%) | 0 (0%) | 0 (0%) | 101 (66%) |
| Other antineoplastic agent§ | 44 (40%) | 9 (41%) | 0 (0%) | 9 (75%) | 1 (100%) | 2 (100%) | 3 (75%) | 68 (44%) |
| Anabolic agents for systemic use‡,§ | 2 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (1%) |
| Antianemic preparations‡,§ | 6 (5%) | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 7 (5%) |
| Antihemorrhagics‡,§ | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) |
| Corticosteroids for systemic use‡,§ | 3 (3%) | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (3%) |
| Immune sera and immunoglobulins‡,§ | 1 (1%) | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (1%) |
| Immunostimulants‡,§ | 13 (12%) | 0 (0%) | 0 (0%) | 2 (17%) | 0 (0%) | 0 (0%) | 1 (25%) | 16 (10%) |
| Immunosuppressants‡,§ | 3 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (2%) |
| Investigational drug‡,§ | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) |
| Unspecified herbal and traditional medicine‡,§ | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) |
| Not reported or cannot report because of active trial§ | 9 (8%) | 4 (18%) | 1 (50%) | 1 (8%) | 0 (0%) | 0 (0%) | 0 (0%) | 15 (10%) |
| Therapy class . | Final study diagnosis . | |||||||
|---|---|---|---|---|---|---|---|---|
| MDS (n = 256) . | MDS/MPN overlap (n = 45) . | ICUS (n = 48) . | AML with <30% blasts∗ (n = 14) . | Other AML (n = 3) . | Other malignancy (n = 11) . | Other (n = 41) . | Total (n = 418) . | |
| Any therapy† | 111 (43%) | 22 (49%) | 2 (4%) | 12 (86%) | 1 (33%) | 2 (18%) | 4 (10%) | 154 (37%) |
| Antineoplastic agent‡,§ | 93 (84%) | 17 (77%) | 1 (50%) | 11 (92%) | 1 (100%) | 2 (100%) | 3 (75%) | 128 (83%) |
| Hypomethylating agent§ | 80 (72%) | 12 (55%) | 1 (50%) | 8 (67%) | 0 (0%) | 0 (0%) | 0 (0%) | 101 (66%) |
| Other antineoplastic agent§ | 44 (40%) | 9 (41%) | 0 (0%) | 9 (75%) | 1 (100%) | 2 (100%) | 3 (75%) | 68 (44%) |
| Anabolic agents for systemic use‡,§ | 2 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (1%) |
| Antianemic preparations‡,§ | 6 (5%) | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 7 (5%) |
| Antihemorrhagics‡,§ | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) |
| Corticosteroids for systemic use‡,§ | 3 (3%) | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (3%) |
| Immune sera and immunoglobulins‡,§ | 1 (1%) | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (1%) |
| Immunostimulants‡,§ | 13 (12%) | 0 (0%) | 0 (0%) | 2 (17%) | 0 (0%) | 0 (0%) | 1 (25%) | 16 (10%) |
| Immunosuppressants‡,§ | 3 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (2%) |
| Investigational drug‡,§ | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) |
| Unspecified herbal and traditional medicine‡,§ | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) |
| Not reported or cannot report because of active trial§ | 9 (8%) | 4 (18%) | 1 (50%) | 1 (8%) | 0 (0%) | 0 (0%) | 0 (0%) | 15 (10%) |
The number and percentage of participants with the given therapy received by disease group per final central study assignment is reported in this table. n, the number of participants in each disease group with therapy reviews. Hypomethylating agents include any azacitidine or decitabine reported. Antianemic preparations include vitamin B12, folic acid, iron preparations, erythropoiesis-stimulating agents, and erythroid maturation agents. Participants can receive multiple therapies of different classes; therefore, the number of participants receiving individual therapy may not sum to the total number of participants receiving therapy.
AML with <30% blasts excluding AML with core binding factor or acute promyelocytic leukemia.
Denominator in percentages based on the number of participants with therapy reviews in each disease group.
Therapy classes based on the WHO drug Anatomical Therapeutic Chemical Level 2 classification.
Denominator in percentages based the number of participants receiving any therapy in each disease group.